On April 26-27, 2024, the 2024 Chinese Society of Clinical Oncology (CSCO) Guidelines Conference was held in Jinan, Quancheng. After a year, experts and scholars from various oncology fields across the country gathered together again to focus on the latest research progress, discuss hot spots in clinical practice, clarify ideas and identify directions for the high-quality development of oncology, and jointly witness the update of many CSCO tumor diagnosis and treatment guidelines and the first release of new guidelines.
At 8 o'clock in the morning of April 26, at the site of the 2024 CSCO Guidelines Conference, CSCO officially held a press conference on the 2024 guidelines, under the chairmanship of Professor Jiang Zefei, vice president and secretary general of CSCO, the main leaders of the CSCO Council, Professor Xu Ruihua, Academician Yu Jinming, Professor Li Jin, Professor Ma Jun, Professor Qin Shukui, Professor Guo Jun, Professor Cheng Ying, Professor Liang Jun, and Professor Liang Houjie attended the press conference.
Reporters from nearly 50 domestic media and portals, including Xinhua News Agency, Health News, Shandong Satellite TV, Dazhong Daily, Qilu Evening News, Jinan Daily, Jinan Times, Dazhong.com, Aijinan, and China Medical Tribune, attended the opening ceremony and press conference of the guide.
In the press conference, Professor Xu Ruihua, Chairman of CSCO, and Academician Yu Jinming, President-designate of CSCO, fully introduced and sorted out the development process of the guideline, the update and release of the guideline and its characteristics.
The experts at the meeting answered questions from the media on the first-line clinical application of CSCO guidelines, promotion and popularization planning, the contribution of Chinese research to CSCO guidelines, and the safety management of cancer treatment, demonstrating the mission and responsibility of CSCO as a professional society in the field of oncology in China.
Leading the frontier and based on reality
Formulate CSCO diagnosis and treatment guidelines in line with China's national conditions
Diagnosis and treatment guidelines play a vital role in clinical work, as an important tool to ensure the quality of medical services, improve patient satisfaction, and promote the development of medicine. Based on evidence-based medical evidence, taking into account the accessibility of diagnosis and treatment products, and absorbing the new advances in precision medicine, it is the basic concept and principle of CSCO guideline formulation and updating to formulate guidelines for the diagnosis and treatment of common cancers in China.
Professor Xu Ruihua pointed out that since the first CSCO guidelines for the diagnosis and treatment of lung cancer were released in 2016, a total of 154 CSCO guidelines have been published in the past eight years, with a total circulation of more than 2.2 million copies, which have been highly concerned and praised by clinicians. The update and expansion of the guidelines in the past conferences have continuously injected new impetus into the cause of clinical oncology in China. Over the past 8 years, with the unremitting efforts of CSCO experts and scholars and the enthusiastic feedback of clinicians, the CSCO series of diagnosis and treatment guidelines have made breakthroughs, and have become an important reference and standard of diagnosis and treatment for the majority of cancer clinicians in China, which has greatly promoted the improvement of the clinical diagnosis and treatment level of cancer in China.
With the rapid development of the field of oncology, new technologies and new therapies are emerging one after another, and with the continuous improvement of China's academic strength in the international field, the demand for clinical diagnosis and treatment is also increasing. In the face of the trend of internationalization, the CSCO guidelines continue the tradition, take into account the frontiers at home and abroad and China's medical conditions, and under the guidance of the Guidelines Working Committee, they continue to be updated and improved, providing strong support for the standardized diagnosis and treatment of Chinese cancer patients, and also becoming an important window for China's clinical oncology work to be displayed to the outside world.
Strive for perfection and go far
Promote the comprehensive improvement of clinical diagnosis and treatment of tumors
The CSCO guidelines have attracted much attention not only because of the scientific and standardized content of their content, but also because of their high attention to new treatment methods and common complications. Professor Qin Shukui said that CSCO has always been committed to promoting the standardization of clinical treatment of tumors, and is committed to forming a whole-process management system suitable for cancer patients in China, so as to make continuous efforts for patients to have more survival benefits, lower complication rates and higher clinical cure rates. The CSCO guidelines cooperate with the guidelines published by the National Health Commission, emphasizing more academic significance, quickly and accurately absorbing cutting-edge evidence-based medical evidence and continuously improving it, so as to provide newer, faster and more detailed standardized guidance for clinical diagnosis and treatment. Of course, there are still various individualized diagnosis and treatment problems to be solved in clinical practice, which need to be comprehensively absorbed, integrated and accurately treated by front-line oncologists.
At this guideline conference, CSCO will release 32 guidelines for cancer diagnosis and treatment, of which 1 is the first release, and the remaining 31 are republished and updated. The first published guideline is the Guidelines for the Diagnosis and Treatment of Liver Injury Associated with Oncology Drugs. In order to further protect the benefits of patients and avoid the potential safety hazards brought by anti-tumor therapy, the majority of clinical oncologists should pay more attention to the safety of current tumor treatment. The first edition of the Guidelines for the Diagnosis and Treatment of Liver Injury Associated with Tumor Drugs is another drug safety-related guideline launched by the CSCO Anti-tumor Drug Safety Management Committee after adverse reactions such as thrombocytopenia, anemia, and venous thrombosis associated with tumor treatment, aiming to deal with the risk of drug-induced liver injury (DILI) caused by the single and combined use of drugs in the current cancer treatment, improve the awareness and diagnosis and treatment level of DILI among oncologists in mainland China, and improve the quality of life of patients.
The 31 CSCO guidelines have been republished and updated, covering respiratory, digestive, neurological, urinary, gynecological, breast, blood, head and neck, bone and soft tissue, and other fields, taking into account cutting-edge treatment methods and tumor treatment complications. Professor Guo Jun pointed out that in recent years, mainland oncologists have carried out a considerable number of clinical studies at the international level, which are more targeted and closer to the clinical practice of mainland cancer patients based on the disease characteristics of mainland cancer patients. To this end, when the CSCO guidelines are updated on the basis of the content of previous years, they not only absorb the latest international continuous progress, but also incorporate evidence-based research evidence from mainland China in a timely manner, so as to create a more practical diagnosis and treatment recommendation system that truly targets the characteristics of Chinese tumors, so as to better ensure the timeliness and practicability of the guidelines.
Specialized and versatile
The two fields are parallel to promote the in-depth and comprehensive development of the field
Academician Yu Jinming, as the host of the conference, welcomed the participating experts and colleagues from all walks of life, and said that the conference will have a speaker team composed of 160 experts and scholars who participated in the compilation of the guidelines to deeply interpret the key points of the guidelines for the majority of colleagues in the 23 special sessions of the conference, hoping that with the joint efforts of everyone, we will work together to promote the standardized diagnosis and treatment of clinical tumors across the country, improve the clinical and scientific research level of medical workers at all levels, and embark on a new journey of high-quality development of cancer prevention and treatment.
It is understood that in terms of venue setting, the conference has changed the meeting form of one main venue and each special session in turn in previous years, to a more efficient and convenient dual-venue parallel mode. On the first day of the conference, the main venue 1 focused on nasopharyngeal cancer, esophageal cancer, kidney cancer, gastric cancer, colorectal cancer, breast cancer, gynecological cancer, bone and soft tissue tumors, and immunotherapy, while the main venue 2 focused on head and neck tumors, kidney cancer, prostate cancer, urothelial cancer, neuroendocrine tumors, gastrointestinal stromal tumors, and tumor nutrition therapy. On the second day of the conference, the main venue 1 mainly held a special discussion on solid tumors such as hepatobiliary and pancreatic tumors, melanoma, and lung cancer, and the main venue 2 mainly focused on the in-depth interpretation of guidelines related to hematological malignancies. Special discussions will be held in different tumor sub-venues, and participating scholars can choose different venues according to their interests and needs, which will better promote communication and in-depth discussion in the field, which not only reflects the continuous enrichment of the CSCO series of guidelines, but also provides an opportunity for the in-depth and comprehensive development of the field.
At the same time, Professor Li Jin, chairman of the foundation, said on behalf of the Beijing Heath Clinical Oncology Research Foundation that in order to further promote the standardized construction of clinical oncology and help medical staff at all levels improve the level of diagnosis and treatment and scientific research, To promote the promotion and implementation of the CSCO series of diagnosis and treatment guidelines, with the support of the Foundation and the cooperation of various medical institutions, the special committees of CSCO will continue to carry out a number of activities such as standardized diagnosis and treatment learning and the construction of oncology departments this year, so as to effectively promote the comprehensive development of China's cancer diagnosis and treatment level and contribute to the promotion of "Healthy China 2030"!
Finally, Professor Jiang Zefei said that the leaders of the Society and the Foundation attach great importance to the problem of piracy of the Guide, and on the one hand, they will publish the physical book of the Guide as soon as possible and deliver it to front-line doctors in a timely manner, and on the other hand, the Society will also work together with the publishing house to actively promote the online popularization of the electronic version of the Guide. Professor Jiang also said that the formulation of the CSCO guidelines contains the collective wisdom and hard work of nearly 1,000 oncologists, and called on colleagues to respect intellectual property rights, and the Council will also attach great importance to malicious piracy and crack down on it.
CSCO is committed to promoting the comprehensive development of standardized diagnosis and treatment and academic research in clinical oncology in China. In recent years, more and more Chinese studies have entered the international arena. With the level of clinical research in cancer in China in line with international standards, more and more Chinese data can be used for reference in the formulation and update of CSCO guidelines, and guidelines with more Chinese characteristics and more suitable for China's medical conditions are gradually forming and continuously optimized. It is believed that with the concerted efforts of CSCO experts and the full cooperation of the majority of oncology colleagues, the CSCO guidelines will lead the continuous and high-quality development of cancer diagnosis and treatment practices in China!
Review | CSCO Office: Lv Fang, Liu Jia, Chen Luyao
Edit | China Medical Tribune, Huang Linlin, Liu Qian